Citi added an “upside 30-day catalyst watch” on shares of Nektar (NKTR) while keeping a Buy rating on the name with a $123 price target The firm believes the extension data for rezpegaldesleukin in alopecia areata later this morning could drive meaningful upside in the shares. A positive SALT20 response rate in line with low-dose baricitinib of 21%-25% is achievable, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics: Buy Rating on Favorable Alopecia Areata Rezpeg Data Outlook and 30‑Day Catalyst Upside Potential
- Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Stock Decline
- Nektar announces data from Phase 2b Rezolve-AD, Rezolve-AA studies
- NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Allegedly Concealed Trial Protocol Violations: Levi & Korsinsky
- Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures